home ver. 2.3. site index contact us

Message from the CEO
How We Work
Business Integrity
History of Schering-Plough
Management Team
Schering-Plough Worldwide
Speeches & Presentations
The Schering-Plough Foundation
Diversity & Inclusion
Supplier Registration
Diversity Colleague Demographics

Management Team

PIERRE VERSTRAETE
Group Vice President/President, Latin America Region
Global Pharmaceutical Business

Pierre Verstraete is group vice president and president, Latin America region, for the Global Pharmaceutical Business of Schering-Plough Corporation.

Verstraete joined Schering-Plough in 1986 as general manager, Venezuela, and moved to Mexico as general manager in 1988. He spent a year in the United States as vice president, marketing and then resumed his international career with the company as vice president and general manager for Spain. Prior to his current position, Verstraete served as senior vice president and general manager for France, a position he held since 1996. Verstraete began his career in the pharmaceutical industry in 1982 with Ciba-Geigy as manager for the company's pharmaceutical division in Bogota, Colombia.

Verstraete graduated from University "I.C.A.M.," Institute of Art and Technology, in France, as a mechanical and industrial engineer. He has taken active roles in various pharmaceutical associations in France, Mexico and Spain. During his tenure in Mexico, Verstraete was vice president and president of the U.S. Pharmaceutical Association and was involved in developing and implementing the Pharmaceutical Industry Modernization Program with the Mexican government within the framework of the North American Free Trade Agreement between Canada, the United States and Mexico.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

 

Spotlight On

Combination Brochure

Brochure on the Combination

Basic Facts and Figures
•  World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530
•  Chairman and CEO:
Fred Hassan
Number of employees:
55,000
Net sales (2007):
$12.7 billion
Business operations in more than:
140 countries
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX.
R&D investment (2007):
$2.9 billion
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health

*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
 
                                      © 2003-2008 Schering-Plough Corporation.
                 Please see our legal notice, privacy policy and forward-looking statement.
Schering-Plough Schering-Plough skip to content Schering-Plough